ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-22-552-3840
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees43
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Obseva (NASDAQ:OBSV) Frequently Asked Questions
What is Obseva's stock symbol?
Obseva trades on the NASDAQ under the ticker symbol "OBSV."
How were Obseva's earnings last quarter?
Obseva SA (NASDAQ:OBSV) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.22. View Obseva's Earnings History.
When is Obseva's next earnings date?
What price target have analysts set for OBSV?
4 analysts have issued 12 month price targets for Obseva's stock. Their forecasts range from $16.00 to $44.00. On average, they anticipate Obseva's stock price to reach $32.6667 in the next twelve months. This suggests a possible upside of 270.0% from the stock's current price. View Analyst Price Targets for Obseva.
What is the consensus analysts' recommendation for Obseva?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.
What are Wall Street analysts saying about Obseva stock?
Here are some recent quotes from research analysts about Obseva stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019)
- 2. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (7/31/2019)
Has Obseva been receiving favorable news coverage?
News coverage about OBSV stock has been trending somewhat negative recently, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obseva earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Obseva.
Are investors shorting Obseva?
Obseva saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 557,500 shares, an increase of 125.5% from the July 31st total of 247,200 shares. Based on an average daily volume of 46,500 shares, the short-interest ratio is currently 12.0 days. Approximately 2.5% of the company's stock are short sold. View Obseva's Current Options Chain.
Who are some of Obseva's key competitors?
Some companies that are related to Obseva include Tricida (TCDA), Apellis Pharmaceuticals (APLS), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Pacira Biosciences (PCRX), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA), Gossamer Bio (GOSS) and G1 Therapeutics (GTHX).
What other stocks do shareholders of Obseva own?
Who are Obseva's key executives?
Obseva's management team includes the folowing people:
- Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
- Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
- Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
- Mr. Mario Vincent Corso, Sr. Director of Investor Relations
- Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)
When did Obseva IPO?
(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.
Who are Obseva's major shareholders?
Obseva's stock is owned by a number of of retail and institutional investors. Top institutional investors include First Manhattan Co. (4.54%), AXA (1.10%), Point72 Asset Management L.P. (0.54%), Renaissance Technologies LLC (0.18%), Wedbush Securities Inc. (0.06%) and Capital Investment Advisory Services LLC (0.01%).
Which major investors are selling Obseva stock?
OBSV stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Wedbush Securities Inc. and First Manhattan Co..
Which major investors are buying Obseva stock?
OBSV stock was bought by a variety of institutional investors in the last quarter, including AXA, Renaissance Technologies LLC, Capital Investment Advisory Services LLC, Morgan Stanley and Cubist Systematic Strategies LLC.
How do I buy shares of Obseva?
Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Obseva's stock price today?
One share of OBSV stock can currently be purchased for approximately $8.83.
How big of a company is Obseva?
Obseva has a market capitalization of $401.59 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva.
What is Obseva's official website?
How can I contact Obseva?
Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]
MarketBeat Community Rating for Obseva (NASDAQ OBSV)
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
